Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Combination Trial to Evaluate SNK-01 with Pembrolizumab in Stage IV Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase I/IIa Combination Trial to Evaluate SNK-01 with Pembrolizumab in Stage IV Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SNK 01 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Aug 2022 Primary endpoint (Overall survival (OS)) has not been met, as per results presented at the 2022 World Conference on Lung Cancer.
    • 09 Aug 2022 Results assessing long term efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
    • 15 Nov 2021 According to NKGen Biotech media release, data from this study were presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 10 to 14, 2021, in Washington, D.C.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top